stockportfolio.pro
Masimo Corporation (MASI)
Healthcare · Medical Devices · NasdaqGS
Masimo Corporation revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2021 | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $712.90M | $790.25M | $858.29M | $937.84M | $1.14B | $1.24B | $2.04B | $2.05B | $2.09B | $1.53B |
| Gross profit | $478.34M | $522.03M | $574.89M | $629.17M | $743.00M | $808.40M | $1.06B | $765.60M | $794.30M | $945.20M |
| Net income | $311.10M | $124.79M | $193.54M | $196.22M | $240.30M | $229.60M | $143.50M | $81.50M | $-304.90M | $-151.50M |
| Net margin | 43.6% | 15.8% | 22.5% | 20.9% | 21.0% | 18.5% | 7.0% | 4.0% | -14.6% | -9.9% |
Source: Masimo Corporation SEC filings (10-K). 18 years of history available in the interactive view.
Explore 18 years of Masimo Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track MASI in your portfolio →
About Masimo Corporation
Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide. It offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo Rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of oxygen, carboxyhemoglobin, and methemoglobin. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Iris, iSirona, Replica, and UniView; and brain function monitoring, hemodynamic monitoring, regional oximetry, acoustic respiration rate monitoring, capnography and gas monitoring, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.
Masimo Corporation — frequently asked questions
What is Masimo Corporation's revenue?
Masimo Corporation (MASI) reported revenue of $1.53B for fiscal year 2025, down 27.1% from the prior year, according to its SEC filings.
Is Masimo Corporation profitable?
No — MASI reported a net loss of $-151.50M in fiscal 2025.
What is MASI's P/E ratio?
Masimo Corporation trades at a price-to-earnings ratio of about 44.4 based on the latest data in our nightly-refreshed cache.
How fast is Masimo Corporation growing?
MASI's revenue grew at roughly 5.9% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Masimo Corporation's official SEC filings (10-K and 10-Q), covering 18 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.